Single-Agent versus Combination Therapy in Metastatic Prostate Cancer

PT-112 monotherapy advances to phase 3 trial in metastatic castration-resistant prostate cancer after positive FDA end of phase 2 meeting.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

An ARANOTE substudy showed darolutamide plus ADT significantly improved outcomes (rPFS HR 0.51) and PSA suppression in Black men with mHSPC, with similar safety to overall trial.

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

Prostatectomy for grade group 1 prostate cancer significantly decreased from 2010 to 2024 in SEER and MUSIC data. Remaining cases show more high-risk features.

Frailty assessments, particularly the G8 tool, BMI, and albumin, may identify mHSPC patients at higher risk for severe adverse events with upfront docetaxel, a study suggests.